Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.53 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CPN1 | P15169 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7319347 | 1.00 | CYP2C19 (0.57) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL197934 | 1.00 | CYP2C19 (0.57) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| Hydrochloric Acid SCHEMBL7609245 | 0.98 | CYP2C19 (0.55) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL28332935 | 0.91 | CPN1 (0.48) | CYP2C19GABBR2GABBR1EPHX1CYP2D6 | |
| SCHEMBL27543440 | 0.89 | PTGS2 (0.55) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL1310192 | 0.88 | CHRNB2 (0.57) | CYP2C19GABBR2GABBR1 | |
| SCHEMBL27582649 | 0.86 | GABBR2 (0.53) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL637030 | 0.84 | EPHX1 (0.66) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL12323888 | 0.84 | EPHX1 (0.66) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL11136320 | 0.83 | CYP2C19 (0.40) | CYP2C19GABBR2GABBR1EPHX1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| US-11753445-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230218710-A1 | METHOD OF TREATING CORONAVIRUS INFECTIONS | COHBAR, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230137562-A1 | TAU AGGREGATION INHIBITORS | ADRX, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4135738-A2 | METHOD OF TREATING CORONAVIRUS INFECTIONS | Cohbar Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20220395553-A1 | CXCR4 ANTAGONIST PEPTIDES | COHBAR, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220332774-A1 | THERAPEUTIC MITOCHONDRIAL PEPTIDES | COHBAR, INC. | 2022-10-20 | — | — | US | disclosed |
| US-20220324925-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324912-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2018156892-A1 | PEPTIDE INHIBITORS OF TRANSCRIPTION FACTOR AGGREGATION | ADRX, INC. (US) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018064098-A1 | THERAPEUTIC MOTS-C RELATED PEPTIDES | COHBAR, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-9804168-B2 | Biomarker discovery in complex biological fluid using bead or particle based libraries and diagnostic kits and therapeutics | OPKO PHARMACEUTICALS, LLC (US) | 2017-10-31 | — | — | US | disclosed |
| US-9551721-B2 | Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-01-24 | — | — | US | disclosed |
| US-9551721-B2 | Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-01-24 | — | — | US | disclosed |
| US-9540620-B2 | Methods and compositions for modulating G-alpha-Q signaling | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150218538-A1 | Methods and Compositions for Modulating G-Alpha-Q Signaling | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| US-6417203-B1 | HETEROCYCLIC AMIDES | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-6180627-B1 | INDOLE, INDAZOLE, BENZOTRIAZOLE AND BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2001-01-30 | — | — | US | disclosed |
| EP-0997474-A1 | Antithrombotic agents | PFIZER INC. (US) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | CYP2C19 3397/4885GABBR2 2940/4885GABBR1 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.